Ms. Wendy Johnson has worked for more than 30 years in private and public companies being involved in several M&A. She is the current CBO (and former COO) at Reneo Pharmaceutics (NASDAQ: RPHM).

She was former at ProQuest Investments, a $1B venture fund, CEO of Aires Pharmaceuticals (acquired by Mast Therapeutics); Senior VP at Salmedix Inc. (acquired by Cephalon/Teva); AmpliPhi Biosciences (public), merged to Armata Pharmaceuticals and Board member at MorphoSys AG (public), acquired by Novartis.

She was also former Assistant Director at FDA.